Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bayer Aktienges Ads (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 56,173,800
  • Shares Outstanding, K 3,730,000
  • Annual Sales, $ 46,752 M
  • Annual Income, $ 2,002 M
  • 60-Month Beta 0.99
  • Price/Sales 1.20
  • Price/Cash Flow 5.66
  • Price/Book 0.95
  • Price/Earnings ttm 8.28
  • Earnings Per Share ttm 1.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/20/19
  • Annual Dividend & Yield 0.55 (3.63%)
  • Most Recent Dividend 0.546 on 04/29/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.47
  • Number of Estimates 1
  • High Estimate 0.47
  • Low Estimate 0.47
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -31.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.6100 +1.51%
on 05/31/19
16.0899 -7.83%
on 05/16/19
-0.7200 (-4.63%)
since 05/14/19
3-Month
14.6100 +1.51%
on 05/31/19
19.8000 -25.10%
on 03/19/19
-4.2400 (-22.23%)
since 03/14/19
52-Week
14.6100 +1.51%
on 05/31/19
32.8000 -54.79%
on 06/19/18
-16.8400 (-53.17%)
since 06/14/18

Most Recent Stories

More News
CRISPR Therapeutics Up on Collaboration Expansion by Vertex

CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

BAYRY : 14.8300 (-1.53%)
CRSP : 43.27 (-2.24%)
VRTX : 170.22 (+0.79%)
EDIT : 21.73 (-3.47%)
Blueprint Medicines to File NDA for Avapritinib With FDA

Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

BAYRY : 14.8300 (-1.53%)
BPMC : 90.70 (-0.26%)
RHHBY : 34.5500 (-0.49%)
PFE : 42.76 (+0.61%)
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO

Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.

BAYRY : 14.8300 (-1.53%)
MRK : 82.78 (-0.14%)
RHHBY : 34.5500 (-0.49%)
BMY : 47.56 (+0.49%)
Blueprint Medicines' NDA for Avapritinib on Track for GIST

Blueprint Medicines (BPMC) reports data on avapritinib from NAVIGATOR study for treating patients with PDGFRA Exon 18 mutant GIST and the fourth-line GIST.

BAYRY : 14.8300 (-1.53%)
BPMC : 90.70 (-0.26%)
RHHBY : 34.5500 (-0.49%)
PFE : 42.76 (+0.61%)
Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA

Bayer's (BAYRY) Aliqopa gets Breakthrough Thearpy designation from the FDA for the treatment of adult patients with relapsed marginal zone lymphoma, who have received at least two prior therapies.

BAYRY : 14.8300 (-1.53%)
CELG : 96.51 (+0.07%)
MRK : 82.78 (-0.14%)
BMY : 47.56 (+0.49%)
BioMarin Announces Data on Hemophilia Candidate, Shares Fall

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

BAYRY : 14.8300 (-1.53%)
BMRN : 80.84 (-1.85%)
ALNY : 70.03 (-1.70%)
SNY : 42.47 (-0.49%)
Orphan Drugs Market to Reach US$ 294000 Mn by 2025, Increasing Development of Oncology-related Orphan Drugs to Drive the Market: Fortune Business Insights

The rising prevalence for chronic diseases is a major factor expected to drive the global Orphan Drugs Market during the forecast period. Fortune Business Insights in a recent report, titled "Orphan Drugs...

BAYRY : 14.8300 (-1.53%)
LLY : 111.74 (-0.07%)
AMGN : 176.08 (-0.36%)
PFE : 42.76 (+0.61%)
Monsanto Roundup Lawsuit News: Third Glyphosate Cancer Trial Concludes with $2 Billion Verdict, Bernstein Liebhard LLP Reports

A California jury has ordered Bayer AG to pay more than $2 billion to an elderly couple, both of whom were diagnosed with non-Hodgkin's lymphoma following years of exposure to Monsanto Roundup weed killer....

BAYRY : 14.8300 (-1.53%)
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

BAYRY : 14.8300 (-1.53%)
MRK : 82.78 (-0.14%)
JNJ : 140.09 (-0.44%)
LLY : 111.74 (-0.07%)
ABBV : 78.69 (-0.33%)
RHHBY : 34.5500 (-0.49%)
PFE : 42.76 (+0.61%)
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

BAYRY : 14.8300 (-1.53%)
MRK : 82.78 (-0.14%)
LLY : 111.74 (-0.07%)
AMGN : 176.08 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade BAYRY with:

Key Turning Points

2nd Resistance Point 15.0033
1st Resistance Point 14.9167
Last Price 14.8300
1st Support Level 14.7567
2nd Support Level 14.6833

See More

52-Week High 32.8000
Fibonacci 61.8% 25.8514
Fibonacci 50% 23.7050
Fibonacci 38.2% 21.5586
Last Price 14.8300
52-Week Low 14.6100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar